RE:RE:RE:RE:RE:It's on Twitter... ASCO ResultsSlide #3 shows that pelareorep + paclitaxel met the primary endpoint ORR objective at 16 weeks that the study set out to accomplish.
Slide #4 shows Progression Free Survival (PFS) which showed that pelareorep + paclitaxel PFS surpassed the control PFS by 50% (9.6 months vs 6.4 months).
Consequently, the Bracelet-1 study reproduces the IND-213 study results and serves to reinforce results of IND-213, the prior phase 2 trial that showed a statistically significant near doubling of median overall survival in HR+/HER2- metastatic breast cancer patients treated with pelareorep combined with paclitaxel (21.0 months, n = 28) vs. those treated with paclitaxel alone (10.8 months, n = 29).
So the Bracelet-1 study was a greater success than anyone here has been able to appreciate, because validating pelareorep as a sole acting anti-cancer agent opens the way for pelareorep to be used alone or with various other approved immuno-oncology agents, as listed previously.